Petersen Stine Elleberg, Høyer Morten
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Front Oncol. 2021 Jun 23;11:695647. doi: 10.3389/fonc.2021.695647. eCollection 2021.
There is high-level evidence for addition of androgen deprivation therapy to photon-based radiotherapy of the prostate in intermediate- and high-risk prostate cancer. Little is known about the value of ADT in particle therapy of prostate cancer. We are conducting a systematic review on biochemical disease-free survival, overall survival, and morbidity after combined particle therapy and ADT for prostate cancer.
A thorough search in PubMed, Embase, Scopus, and Web of Science databases were conducted, searching for relevant studies. Clinical studies on prostate cancer and the treatment combination of particle therapy and androgen deprivation therapy were included. The review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and registered on PROSPERO (CRD42021230801).
A total of 298 papers were identified. Fifteen papers reporting on 7,202 patients after proton or carbon-ion therapy for localized prostate cancer where a fraction or all patients received ADT were selected for analysis. Three thousand five hundred and nineteen (49%) of the patients had received combined ADT and particle therapy. Primarily high-risk (87%), to a lesser extent intermediate-risk (34%) and low-risk patients (12%) received ADT. There were no comparative studies on the effect of ADT in patients treated with particles and no studies identified ADT as an independent prognostic factor related to survival outcomes.
The review found no evidence to support that the effects on biochemical disease-free survival and morbidity of combining ADT to particle therapy differs from the ADT effects in conventional photon based radiotherapy. The available data on the topic is limited.
对于中高危前列腺癌患者，在基于光子的前列腺放疗中加入雄激素剥夺治疗有高级别证据支持。而关于雄激素剥夺治疗在前列腺癌粒子治疗中的价值，人们知之甚少。我们正在对前列腺癌粒子治疗联合雄激素剥夺治疗后的生化无病生存期、总生存期和发病率进行系统评价。
全面检索了PubMed、Embase、Scopus和Web of Science数据库，以查找相关研究。纳入了关于前列腺癌以及粒子治疗与雄激素剥夺治疗联合应用的临床研究。本评价按照系统评价和Meta分析的首选报告项目（PRISMA）指南进行，并在PROSPERO（CRD42021230801）上进行了注册。
共识别出298篇论文。选取了15篇报道7202例局限性前列腺癌患者接受质子或碳离子治疗后情况的论文进行分析，其中部分或全部患者接受了雄激素剥夺治疗。3519例（49%）患者接受了雄激素剥夺治疗与粒子治疗联合方案。主要是高危患者（87%），其次是中危患者（34%）和低危患者（12%）接受了雄激素剥夺治疗。没有关于雄激素剥夺治疗对接受粒子治疗患者疗效的对比研究，也没有研究将雄激素剥夺治疗确定为与生存结果相关的独立预后因素。
本评价未发现证据支持雄激素剥夺治疗联合粒子治疗对生化无病生存期和发病率的影响与在传统光子放疗中的影响不同。关于该主题的现有数据有限。
